News

April 12, 2022

Enteris BioPharma Announces Acceptance of Two Abstracts for Presentation at ENDO 2022 Annual Conference

Boonton, NJ, April 12, 2022  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
April 4, 2022

Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologies for Improving Drug Solubility and Bioavailability

Article describes unique features of Enteris’ Peptelligence® and ProPerma® peptide and small molecule oral delivery technology Boonton, NJ, April 4, 2022  — Enteris BioPharma, Inc., a biotechnology […]
March 7, 2022

Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufacturing with HPAPI

Paper examines barriers to achieving optimal content uniformity with HPAPIs and the techniques manufacturers should use with low-dose drug products. Boonton, NJ, March 7, 2022  — Enteris […]
March 1, 2022

Enteris BioPharma to Participate in DCAT® Week 2022

Boonton, NJ, March 1, 2022  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
February 15, 2022

Enteris BioPharma Highlights Progress in Oral Feasibility Program

Six feasibility programs underway for oral tablet formulations developed with Enteris’ Peptelligence® and ProPerma® technology platforms Boonton, NJ, February 15, 2022  — Enteris BioPharma, Inc., a biotechnology […]
January 10, 2022

Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services

Boonton, NJ, January 10, 2022  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
January 6, 2022

Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook

Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms Received two milestone payments totaling $15 million from Cara Therapeutics per license […]

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE